Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
EVAX | US
-0.22
-5.18%
Healthcare
Biotechnology
30/06/2024
24/04/2026
4.03
4.27
4.27
4.00
Evaxion Biotech A/S a clinical-stage biotech company engages in developing artificial intelligence-powered immunotherapies for cancers bacterial diseases and viral infections. The company develops EVX-01 a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02 a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03 a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1 EVX-B2 and EVX-V1 which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm Denmark.
View LessLow Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
54.7%1 month
58.5%3 months
83.6%6 months
88.9%-
3.57
12.06
8.37
0.69
-0.59
63.35
-
-18.80M
22.48M
22.48M
-
-2.97K
-
-
-802.80
0.90
2.14
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.83
Range1M
1.40
Range3M
1.84
Rel. volume
1.03
Price X volume
126.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CELU | CELU | Biotechnology | 1.11 | 24.40M | -0.89% | n/a | 127.38% |
| Edesa Biotech Inc | EDSA | Biotechnology | 7.26 | 23.58M | 7.08% | n/a | 1.35% |
| QNRX | QNRX | Biotechnology | 5.7 | 22.69M | -0.52% | n/a | 43.11% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.8566 | 20.55M | -4.82% | n/a | 0.00% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 6.4 | 20.46M | 4.40% | n/a | 14.63% |
| Enlivex Therapeutics Ltd | ENLV | Biotechnology | 0.8885 | 19.02M | -2.01% | n/a | 2.92% |
| Inhibikase Therapeutics Inc. | IKT | Biotechnology | 1.88 | 18.75M | -2.59% | n/a | 3.49% |
| PLUR | PLUR | Biotechnology | 3.345 | 18.30M | -2.76% | n/a | 30845.83% |
| DOMH | DOMH | Biotechnology | 2.89 | 18.14M | 0.00% | n/a | 7.66% |
| DarT Bioscience Inc | DARE | Biotechnology | 2.11 | 18.03M | -0.47% | 0.12 | 218.34% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0055 | 507.18K | -37.50% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | 0.53 | Cheaper |
| Ent. to Revenue | 63.35 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 12.06 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 83.60 | 72.80 | Par |
| Debt to Equity | 8.37 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 22.48M | 3.66B | Emerging |